artenimol has been researched along with Psoriasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, G; Chen, B; Li, C; Wang, H | 1 |
| Chen, Y; Dai, Z; Han, L; Huang, RY; Liang, CL; Liu, H; Lu, C; Qiu, F; Yan, Y; Zhang, Q | 1 |
2 other study(ies) available for artenimol and Psoriasis
| Article | Year |
|---|---|
Dihydroartemisinin targets fibroblast growth factor receptor 1 (FGFR1) to inhibit interleukin 17A (IL-17A)-induced hyperproliferation and inflammation of keratinocytes.
Topics: Animals; Anti-Inflammatory Agents; Artemisinins; Cell Differentiation; Cell Line; Cell Proliferation; Cell Survival; Humans; Interleukin-17; Keratinocytes; Mice; Models, Biological; Psoriasis; Receptor, Fibroblast Growth Factor, Type 1; Up-Regulation | 2022 |
Dihydroartemisinin ameliorates psoriatic skin inflammation and its relapse by diminishing CD8
Topics: Animals; Artemisinins; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Imiquimod; Immunologic Memory; Interleukin-15; Interleukin-17; Male; Methotrexate; Mice; Psoriasis; Recurrence; Secondary Prevention; Skin; Skin Transplantation; Transplantation Chimera | 2020 |